We are live on ! Find out more
EBAC

European Biotech Acquisition Corp. Class A Ordinary Shares
EBAC

Delisted

EBAC was delisted on the 2nd of March, 2023.

Back to rankings

45 hedge funds and large institutions have $69.6M invested in European Biotech Acquisition Corp. Class A Ordinary Shares in 2021 Q4 according to their latest regulatory filings, with 6 funds opening new positions, 4 increasing their positions, 1 reducing their positions, and 2 closing their positions.

New
Increased
Maintained
Reduced
Closed

300% more repeat investments, than reductions

Existing positions increased: 4 | Existing positions reduced: 1

200% more first-time investments, than exits

New positions opened: 6 | Existing positions closed: 2

26% more capital invested

Capital invested by funds: $55.2M → $69.6M (+$14.4M)

10% more funds holding

Funds holding: 41 → 45 (+4)

Holders
45
Holders Change
+4
Holders Change %
+9.76%
% of All Funds
0.69%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
6
Increased
4
Reduced
1
Closed
2
Calls
$8K
Puts
–
Net Calls
+$8K
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
HP
Hartree Partners
New York
+$7.3M
2
PC
Periscope Capital
Ontario, Canada
+$4.52M
3
D.E. Shaw & Co
D.E. Shaw & Co
New York
+$1.61M
4
AMH
Apollo Management Holdings
New York
+$971K
5
Marshall Wace
Marshall Wace
United Kingdom
+$856K

Top Sellers

Rank Fund Capital Flow
1
AC
Athanor Capital
New York
-$1.43M
2
Millennium Management
Millennium Management
New York
-$87.7K
3
WAM
Wolverine Asset Management
Illinois
-$4K
Name Holding Trade Value Shares
Change 		Change in
Stake
GF
26
Gabelli Funds
New York
$710K – – –
GCIA
27
Gabelli & Co Investment Advisers
New York
$637K – – –
WA
28
Whitebox Advisors
Minnesota
$528K – – –
SCC
29
Spring Creek Capital
Kansas
$485K – – –
EAM
30
Exos Asset Management
New York
$439K – – –
ACM
31
Atalaya Capital Management
New York
$388K – – –
MP
32
Mangrove Partners
Connecticut
$383K – – –
VI
33
Vestcor Inc
New Brunswick, Canada
$340K – – –
OAC
34
OMERS Administration Corp
Ontario, Canada
$339K – – –
KCM
35
Kawa Capital Management
Florida
$262K +$263K +27,000 New
WRBC
36
W.R. Berkley Corp
Connecticut
$190K – – –
DIG
37
DeepCurrents Investment Group
New York
$172K +$173K +17,730 New
LCM
38
Landscape Capital Management
New Jersey
$106K – – –
MF
39
Magnetar Financial
Illinois
$100K – – –
PCM
40
Prelude Capital Management
New York
$97K – – –
AA
41
Ancora Advisors
Ohio
$68K – – –
PCM
42
Pinz Capital Management
New York
$23K +$22.7K +2,331 New
GCL
43
Glazer Capital LLC
New York
$19K – – –
DFCM
44
Dark Forest Capital Management
Puerto Rico
$15K +$15.4K +1,579 New
UBS Group
45
UBS Group
Switzerland
$2K – – –
AC
46
Athanor Capital
New York
– -$1.43M -147,800 Closed
WAM
47
Wolverine Asset Management
Illinois
– -$4K -499 Closed
1
2

EBAC Hedge Fund Activity: Q4 2021 in Review

45 of the 6,499 institutional investors tracked by Wall St. Rank reported a position in European Biotech Acquisition Corp. Class A Ordinary Shares (EBAC) for Q4 2021, worth a combined $69.6M — up 26% from $55.2M a quarter earlier.

Buyers outnumbered sellers: 6 funds opened new EBAC positions and 2 closed out — a net gain of 4 holders — while 4 added to existing stakes and 1 trimmed.

The largest buyer was Hartree Partners, opening a new position worth an estimated $7.3M. The largest seller was Athanor Capital, exiting entirely with an estimated $1.43M sold.

  • 45 institutional investors held European Biotech Acquisition Corp. Class A Ordinary Shares (EBAC) as of Q4 2021, up from 41 in Q3 2021.
  • Funds reported $69.6M of European Biotech Acquisition Corp. Class A Ordinary Shares stock for Q4 2021, up 26% quarter-over-quarter.
  • 6 funds opened new European Biotech Acquisition Corp. Class A Ordinary Shares positions in Q4 2021 and 2 closed out, a net change of +4 holders.
  • The largest European Biotech Acquisition Corp. Class A Ordinary Shares buyer in Q4 2021 was Hartree Partners, an estimated $7.3M added.
  • The largest European Biotech Acquisition Corp. Class A Ordinary Shares seller in Q4 2021 was Athanor Capital, an estimated $1.43M sold.

Based on aggregated 13F filings for Q4 2021.